carbostyril has been researched along with Bacterial Infections in 209 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 21 (10.05) | 18.7374 |
| 1990's | 103 (49.28) | 18.2507 |
| 2000's | 41 (19.62) | 29.6817 |
| 2010's | 37 (17.70) | 24.3611 |
| 2020's | 7 (3.35) | 2.80 |
| Authors | Studies |
|---|---|
| Bucarey, SA; Hidalgo, AA; Millanao, AR; Mora, AY; Villagra, NA | 1 |
| Gao, Y; Han, T; Liu, H; Qian, B; Zhang, X | 1 |
| Abraldes, JG; Albillos, A; Alvarado, E; Amitrano, L; Bañares, R; Bosch, J; Bureau, C; Calleja, JL; Cañete, N; Casas, M; Castellote, J; Catalina, MV; Conejo, I; Dell'Era, A; Ferlitsch, A; Fischer, P; García-Pagán, JC; Genescà, J; Giráldez, Á; Gluud, LL; Gronbaek, H; Guardascione, MA; Hernández-Gea, V; Hernández-Guerra, M; Ibañez-Samaniego, L; Jansen, C; Krag, A; Laleman, W; Llop, E; Martínez, J; Masnou, H; Mundi, JL; Nevens, F; Noronha-Ferreira, C; Palazon, JM; Perez-Campuzano, V; Primignani, M; Procopet, B; Robic, MA; Rodrigues, S; Rodríguez, M; Rodríguez-de-Santiago, E; Romero-Gomez, M; Rudler, M; Sassatelli, R; Schwarzer, R; Senzolo, M; Silva-Junior, G; Téllez, L; Thabut, D; Trebicka, J; Villanueva, C; Zipprich, A | 1 |
| Desprez, C; Gourcerol, G; Leroi, AM; Melchior, C; Richard, N; Wuestenberghs, F | 1 |
| Adriaenssens, N; Bruyndonckx, R; Coenen, S; Goossens, H; Hens, N; Molenberghs, G; Monnet, DL; Versporten, A; Weist, K | 1 |
| Togo, Y; Yamamoto, S | 1 |
| Bhargava, P; Collins, JJ; Gutierrez, A; Hamblin, M; Jain, S; Lobritz, MA | 1 |
| Amitharaj, R; Chadwick, D; Fitzpatrick, J; Jones, P; Noreikaite, J; Pietropaolo, A; Rai, BP; Somani, BK; Vasdev, N | 1 |
| Masarwa, R; Matok, I; Perlman, A; Ziv, A; Ziv, D | 1 |
| Celhay, O; Coast, J; Cooper, BS; Do Thi Thuy, N; Guerin, PJ; Lubell, Y; Oppong, R; Phodha, T; Shrestha, P; Wertheim, H | 1 |
| Bruno, R; Fagiuoli, S; Lombardi, A; Zuccaro, V | 1 |
| Angeli, P; Bernardi, M | 1 |
| Ardolino, E; Patwardhan, VR; Wang, SS | 1 |
| Bon, D; Göttig, S; Herrmann, E; Hogardt, M; Kempf, VAJ; Kessel, J; Lange, CM; Mayer, A; Mücke, MM; Mücke, VT; Queck, A; Reinheimer, C; Rüschenbaum, S; Schwarzkopf, K; Vermehren, A; Vermehren, J; Weiler, N; Welker, MW; Zeuzem, S | 1 |
| Guan, X; Jiang, H; Liu, Y; Pan, L; Wang, J; Wang, K; Wang, N; Wang, Y; Xue, X; Yang, B; Zhang, L | 1 |
| Kumar, A; Srivastava, N | 1 |
| Driessen, AJ; Feringa, BL; Hansen, MJ; Szymanski, W; van der Berg, JP; Velema, WA | 1 |
| Alcera, E; Coffey, DB; Patel, S; Tosyali, PM; Varas, DB | 1 |
| Pierris, N; Stamatiou, K | 1 |
| Aldred, KJ; Kerns, RJ; Osheroff, N | 1 |
| Van Bambeke, F | 1 |
| Poole, RM | 1 |
| Gropper, S | 1 |
| Falagas, ME; Trigkidis, KK; Vardakas, KZ | 1 |
| Bisacchi, GS | 1 |
| Marks, DI | 1 |
| Hooper, DC; Jacoby, GA | 1 |
| Aleman, PA; Antón-Fos, GM; Bueso-Bordils, JI; Duart, MJ; Martin-Algarra, R; Zamora, LL | 1 |
| Ahmad, N; Badshah, SL; Khan, K; Muska, M; Naeem, A | 1 |
| Xu, H; Yan, L | 1 |
| Byun, SS; Hong, SK; Lee, JK; Lee, S; Lee, SE | 1 |
| Calvo, J; Cano, ME; Machuca, J; Martínez-Martínez, L; Pascual, A; Rodríguez-Martínez, JM | 1 |
| Alberg, T; Blix, HS; Eriksen, HM; Holen, Ø; Neteland, MI; Smith, I | 1 |
| Cambau, E; Corbel, C; Lascols, C; Liassine, N; Soussy, CJ; Zulueta-Rodriguez, P | 1 |
| Abbanat, D; Bush, K; Morrow, B | 1 |
| Siddiqui, AA | 1 |
| Broelsch, CE; Canbay, A; Gerken, G; Saner, FH | 1 |
| Alós, JI | 1 |
| Bradbury, BJ; Pucci, MJ; Wiles, JA | 1 |
| Murthy, KR; Praveen, B; Rajanarendar, E; Raju, S; Rao, MS; Reddy, KG; Reddy, MN; Srinivas, M | 1 |
| Hori, S | 1 |
| Adriaenssens, N; Aerts, M; Coenen, S; Faes, C; Goossens, H; Hens, N; Minalu, G; Molenberghs, G; Muller, A; Vankerckhoven, V; Versporten, A | 2 |
| Fraser, A; Gafter-Gvili, A; Kremer, LC; Lawrie, TA; Leibovici, L; Paul, M; van de Wetering, MD; Vidal, L | 1 |
| Dasgupta, A | 1 |
| Bourrel, R; Gallini, A; Taboulet, F | 1 |
| Gomes, C; Pons, MJ; Ruiz, J | 1 |
| Blondeau, JM; Farshad, S | 1 |
| Carretero, M; de Lucas, JJ; Forés, P; González, F; Nieto, J; Rodríguez, C; San Andrés, MD; San Andrés, MI; Waxman, S | 1 |
| Bernard, S; Bousquet-Melou, A; Schneider, M; Toutain, PL | 1 |
| Hecht, DW; Osmolski, JR | 1 |
| Andersson, MI; MacGowan, AP | 1 |
| Niki, Y | 2 |
| Andrews, JM; Brenwald, NP; Fraise, AP; Harnett, SJ; Jevons, G; Wise, R | 1 |
| Frothingham, R | 1 |
| Murakawa, GJ; Sable, D | 1 |
| Acar, JF; Kroemer, S; Martel, JL; Meunier, D; Vallé, M | 1 |
| Boothe, D; Chandler, J; Cohen, N; Epstein, K; Nieuwoudt, C | 1 |
| Michot, JM; Tulkens, PM; Van Bambeke, F; Van Eldere, J | 1 |
| Fraser, A; Gafter-Gvili, A; Kremer, L; Leibovici, L; Paul, M; van de Wetering, M | 1 |
| Jones, RN | 1 |
| Rossolini, GM; Satta, G; Vaiani, G; Valentini, S | 1 |
| Carlone, NA; Cuffini, AM; Tullio, V; Vaiani, G | 1 |
| Smith, JT | 1 |
| Ball, P | 1 |
| Bassily, S; El Masry, NA; Haberberger, RL; Mikhail, I; Woody, JN; Yassa, M; Zakaria, S | 1 |
| Almyroudis, NG; Segal, BH | 1 |
| Mirelis, B; Prats, G; Rossi, V; Salvatori, E | 1 |
| Coenen, S; Dvorakova, K; Ferech, M; Goossens, H; Hendrickx, E; Malhotra-Kumar, S; Suetens, C | 1 |
| Chang, MT; Huang, CY; Jang, TN; Wang, CY; Wu, TH | 1 |
| Fuchigami, T; Kaku, M; Kuwabara, M; Rikitomi, N; Totsuka, K | 1 |
| Garcia-Tsao, G; Ghassemi, S | 1 |
| De Lucas, JJ; González, F; Nieto, J; Rodríguez, C; San Andrés, MD; San Andrés, MI; Serres, C; Waxman, S | 1 |
| Bellussi, L; De Benedetto, M; Lauriello, M; Passali, D; Passali, GC | 1 |
| Viscoli, C | 1 |
| Hodson, ME | 1 |
| Gomis Gavilán, M; Prieto Prieto, J | 1 |
| Giamarellou, H | 1 |
| Andrews, JM; Cook, PJ; Honeybourne, D; Moudgil, H; Wise, R | 1 |
| Imada, T; Mukai, F; Ohguro, K; Ohmori, K; Tamaoka, H; Wakebe, H; Yabuuchi, Y; Yoneda, H | 1 |
| Finegold, SM; Molitoris, E; Reeves, D; Wexler, HM | 1 |
| Aldridge, KE | 1 |
| Arakawa, S; Ban, Y; Hirose, T; Ito, Y; Kamidono, S; Kawada, Y; Kumamoto, Y; Kumon, H; Ohmori, H; Suzuki, K | 1 |
| Acar, J; Baquero, F; Bergan, T; Degener, J; Forsgren, A; Phillips, I; Schito, GC; Wiedemann, B | 1 |
| Alder, J; Beyer, J; Chu, DT; Clement, JJ; Hensey, D; McDaniel, D; Ramer, N; Tanaka, SK; Vojtko, C | 1 |
| Mitsuhashi, S; Wakabayashi, E | 1 |
| Akieda, Y; Itokawa, K; Kawaguchi, H; Kawamura, H; Nakayama, I; Suzuki, T; Watanabe, T; Yamaji, E | 1 |
| Denis, A; Moreau, NJ | 1 |
| Verhoef, J | 1 |
| Finegold, SM; Molitoris, E; Wexler, HM | 1 |
| Ahlén, S; Malmborg, AS | 1 |
| Deamer, RL; Heming, D; James, RE; Koenker, N; Prichard, JG | 1 |
| Mattie, H | 1 |
| Oliaro, A | 1 |
| Cho, N; Matsuda, S; Okada, H; Shimizu, T | 1 |
| Inoue, Y; Jinbo, Y; Kondo, H; Kotera, Y; Sakamoto, F; Taguchi, M; Tsujishita, H; Tsukamoto, G | 1 |
| Hosaka, M; Kinoshita, S; Nishino, T; Otsuki, M; Toyama, A | 1 |
| Borcherding, SM; Corley, CR; Nicholas, RA; Self, T; Stevens, R | 1 |
| Lee, DK | 1 |
| Ito, K; Izumi, K; Kawazoe, K; Mikamo, H; Tamaya, T | 1 |
| Eiseman, IA; McGuire, NM; Tack, KJ | 1 |
| Iyobe, S; Mitsuhashi, S; Nakane, T; Sato, K | 1 |
| Ibuki, E; Masuda, N; Miyoshi, H; Nishino, T; Otsuki, M; Takahashi, Y | 1 |
| Abdulla, AM | 1 |
| Jones, RN; Marshall, SA; Zerva, L | 1 |
| Nord, CE | 1 |
| Goldstein, EJ | 1 |
| Kato, H; Kato, N; Tanaka-Bando, K; Ueno, K; Watanabe, K | 1 |
| Gracida, C; Melchor, JL | 1 |
| Aldridge, KE; Ashcraft, DS | 1 |
| Amano, H; Fukuhara, S; Kanachi, K; Kawasaki, T; Ohno, T; Okuma, M; Sasada, M; Suzuki, T; Yasuda, N; Yumoto, Y | 1 |
| Balfour, JA; Wagstaff, AJ | 1 |
| Choi, EC; Choi, KH; Hong, JS; Kim, SK; Lee, DK; Yoon, SJ | 1 |
| Salmon, SA; Sanchez, MS; Watts, JL; Yancey, RJ | 1 |
| Choi, EC; Kang, JA; Kim, BK; Kim, JH; Kim, JW; Kim, YG; Lee, JH | 1 |
| Awad-Masalmeh, M; Krassnig, G; Schuh, M; Schweighardt, H; Truschner, K; Werner-Tutschku, M | 1 |
| Kato, H; Kato, N; Tanaka-Bandoh, K; Ueno, K; Watanabe, K | 1 |
| Jansen, PL | 1 |
| Andrews, JM; Wise, R | 1 |
| Heisig, P; Wiedemann, B | 1 |
| Amantea, MA; Chodosh, S; Collins, DA; Forrest, A; Schentag, JJ | 1 |
| Breisch, S; Cranfield, R; Langan, CE; Pettit, R | 1 |
| Schwabe, R; Stahlmann, R | 1 |
| Norrby, SR | 1 |
| Choi, EC; Choi, KH; Kim, BK; Kim, JH; Kim, JW; Lee, JH | 1 |
| Cohen, MA; Gage, JW; Huband, MD; Roland, GE; Yoder, SL | 1 |
| Bailey, TA; Garner, A; Harron, DW; Samour, JH; Sheen, RS; Silvanose, C | 1 |
| Amiot, X; Grangé, JD | 1 |
| Dea, P; Estany, A; Fisher, DL; Muchlinski, AE; Salguero, HS; Tan, GJ | 1 |
| Dorr, MB; Lipsky, BA; Magner, DJ; Talbot, GH | 1 |
| Bagby, B; Bettis, R; Collins, JJ; DeAbate, CA; Fleming, H; Giguere, G; Munk, ZM; Munn, NJ; Riffer, E | 1 |
| Araki, H; Minami, S; Mitsuyama, J; Narita, H; Takahata, M; Todo, Y; Watanabe, Y; Yamashiro, Y; Yonezawa, M | 1 |
| Garcia, C; Gramajo, R; Muchlinski, AE | 1 |
| Aarestrup, FM; Jensen, NE; Jorsal, SE; Nielsen, TK | 1 |
| Padeĭskaia, EN | 1 |
| Menon, D; Pickard, AS; Spooner, CH | 1 |
| Brown, MP; Gronwall, RR; Haines, GR; Merritt, KA | 1 |
| Chang, BS; Lee, BJ; Lee, YS; Park, BK; Yoo, HS | 1 |
| Domon, H; Furuya, N; Ishii, Y; Matsumoto, T; Miyazaki, S; Murata, M; Ohno, A; Takahashi, Y; Tateda, K; Yamaguchi, K; Yoshizumi, S | 1 |
| Matowe, WC; Phillips, OA | 1 |
| Shah, PM | 1 |
| Schurz, JK | 1 |
| Hafner, D; Kresken, M | 1 |
| Coll, R; Ferrer, S; Gargallo-Viola, D; Guinea, J; Robert, M; Roser, R; Tudela, E | 1 |
| Akasaka, T; Chiba, M; Sato, K; Takemura, M; Tanaka, M; Yamazaki, E; Yoshihara, K | 1 |
| Frechette, R | 1 |
| Gordon, KA; Jones, RN; Pfaller, MA | 1 |
| Bas, L; Deĝim, T; Deĝim, Z; Elmas, M | 1 |
| Chang, P; Cisek, EP; Cornell, CP; Elliott, NC; Gootz, TD; Haskell, SL; Hindahl, MS; Jefson, MR; Mann, DD; McGuirk, PR | 1 |
| Hibi, H; Horiba, M; Naide, Y; Shinoda, M; Suzuki, K | 1 |
| Bruce-Jones, P; Crome, P | 1 |
| Rizk, E | 1 |
| Akaniro, JC; Arguedas, AG; Stutman, HR; Vargas, OM | 1 |
| Goto, S; Imada, T; Miyazaki, S; Nishida, M; Yamaguchi, K | 1 |
| Nix, DE; Symonds, WT | 1 |
| Aoyama, H; Fukuda, H; Hirai, K; Hosaka, M; Tomizawa, H; Yasue, T | 1 |
| Arakawa, S; Kamidono, S | 1 |
| Gutmann, L; Richard, P | 1 |
| Almodovar, E; Burns, JJ; Qadri, SM; Rabea, N; Ueno, Y | 1 |
| Bouzard, D; Di Cesare, P; Fung-Tomc, J; Hoffmann, P; Kessler, R | 1 |
| Lumio, J | 1 |
| Naber, KG | 1 |
| Shimizu, K | 1 |
| Forsgren, A; Paulsen, O | 1 |
| Bischoff, W; Boerema, JB; Focht, J; Naber, KG | 1 |
| Matsumoto, F; Soejima, R | 1 |
| Parish, LC; Witkowski, JA | 1 |
| Jungkind, DL; Parish, LC | 1 |
| Childs, SJ; Cox, CE | 1 |
| Pernet, AG | 1 |
| Pankey, GA | 1 |
| Acar, J; Baquero, F; Bergan, T; Forsgren, A; Phillips, I; Wiedemann, B | 1 |
| Goa, KL; Wadworth, AN | 1 |
| Albrecht, HA; Beskid, G; Christenson, JG; Durkin, JW; Fallat, V; Georgopapadakou, NH; Keith, DD; Konzelmann, FM; Lipschitz, ER; McGarry, DH | 1 |
| Babish, JG; Bowser, PR | 1 |
| Chu, DT; Clement, JJ; Hardy, DJ; Shipkowitz, NL; Swanson, RN | 1 |
| Esteve, M; Gargallo-Viola, D; Guinea, J; Llovera, S; Roca, X | 1 |
| Petzinger, E | 1 |
| Hoffmann, R; Pfeil-Putzien, C; Reimlinger, M; Scheinert, P | 1 |
| Domagala, JM; Hagen, SE; Heifetz, CL; Sanchez, JP; Solomon, M | 1 |
| Butler, K; Gress, J; Lecciones, J; Lee, J; Marshall, D; Pizzo, PA; Roilides, E; Rubin, M; Walsh, T; Weinberger, M | 1 |
| Klastersky, J | 1 |
| Kot, T; Pettit-Young, N | 1 |
| Bodey, GP; Ho, DH; LeBlanc, B; Rolston, KV | 1 |
| Deuel, DM; Dobson, RA; Lesher, GY; Rake, JB; Sedlock, DM | 1 |
| Chambers, ST | 1 |
| Régnier, B; Wolff, M | 1 |
| Adam, D | 1 |
| Graber, H | 1 |
| Kotera, Y; Mitsuhashi, S | 1 |
| Aoki, T; Kanehisa, N; Matsubara, Y; Murata, M; Nitta, Y; Sagara, H; Seo, T; Shimizu, N; Takizawa, Y; Tomizawa, I | 1 |
| Bodey, GP; Gooch, G; Ho, DH; LeBlanc, B; Rolston, KV | 1 |
| Colombrita, D; Foresti, I; Peroni, L; Pinsi, G; Pirali, F; Ravizzola, G; Turano, A | 1 |
| Kunii, O; Ono, Y | 1 |
| Shimada, K | 1 |
| Edwards, R; Greenwood, D; Kanematsu, M | 1 |
| Aoki, Y; Kasano, Y; Kitamura, T; Mukaihara, S; Nakai, T; Tamura, K; Tanimura, H; Terao, R; Uesaka, K; Yotsumoto, F | 1 |
| Hirose, T; Inoue, M; Ito, Y; Kato, H; Mitsuhashi, S; Okezaki, E | 1 |
| Coll, R; Esteve, M; Moros, M; Parés, J; Xicota, MA | 1 |
| Evans, RT; Furr, PM; Harris, JR; Hawkins, DA; Taylor-Robinson, D | 1 |
67 review(s) available for carbostyril and Bacterial Infections
| Article | Year |
|---|---|
Biological Effects of Quinolones: A Family of Broad-Spectrum Antimicrobial Agents.
Topics: Anti-Infective Agents; Bacterial Infections; DNA Gyrase; DNA Topoisomerase IV; DNA, Bacterial; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Quinolones; RNA, Bacterial; Topoisomerase II Inhibitors | 2021 |
Prophylactic antibiotics on patients with cirrhosis and upper gastrointestinal bleeding: A meta-analysis.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; beta-Lactams; Gastrointestinal Hemorrhage; Humans; Liver Cirrhosis; Quinolones | 2022 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosphate; Adsorption; Adult; Africa, Eastern; Aged; Air Pollutants; Air Pollution; Air Pollution, Indoor; Alcohol Drinking; Allergens; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Anti-Bacterial Agents; Antibodies; Antibodies, Immobilized; Antigen Presentation; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Aptamers, Nucleotide; Asthma; Asthma, Exercise-Induced; Atrophy; Autophagy; Azoospermia; Bacillus cereus; Bacterial Infections; Beclin-1; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biofouling; Biological Monitoring; Biomarkers; Biomarkers, Tumor; Biosensing Techniques; Blastocyst; Bone Neoplasms; Bone Regeneration; Bronchoconstriction; Burkitt Lymphoma; C9orf72 Protein; Campylobacter; Campylobacter Infections; Campylobacter jejuni; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Cardiomyopathies; Caregivers; Carmine; Case-Control Studies; Catalysis; Cattle; Cause of Death; CCAAT-Enhancer-Binding Protein-alpha; CD8-Positive T-Lymphocytes; Cefepime; Cell Differentiation; Cell Line, Tumor; Cell Nucleus; Cell Transdifferentiation; Chelating Agents; Chemical and Drug Induced Liver Injury, Chronic; Chemoradiotherapy, Adjuvant; Child; Child, Preschool; China; Chlorquinaldol; Cholangiocarcinoma; Cholera; Chromatin; Clinical Trials as Topic; Cognitive Dysfunction; Cohort Studies; Colonic Neoplasms; Colorectal Neoplasms; Colorimetry; Cooking; Coordination Complexes; COVID-19; Creatinine; CRISPR-Cas Systems; Critical Care; Critical Illness; Cross-Sectional Studies; Cryopreservation; Cryoprotective Agents; Cysteine; Cytokines; Device Removal; Diet; Diet, High-Fat; Diet, Mediterranean; Dietary Supplements; Dimethyl Sulfoxide; Dipeptides; Disease Models, Animal; Dithiothreitol; DNA; DNA Repeat Expansion; DNA, Bacterial; DNA, Complementary; Dopamine; Electrochemical Techniques; Electrodes; Endocannabinoids; Environmental Exposure; Environmental Monitoring; Environmental Pollutants; Enzyme-Linked Immunosorbent Assay; Erlotinib Hydrochloride; Escherichia coli; Escherichia coli O157; Esophageal Neoplasms; Esophagitis, Peptic; Ethylene Glycol; Europium; Exanthema; Fallopian Tubes; Feces; Female; Fertilization in Vitro; Fluoresceins; Fluorescent Dyes; Follicle Stimulating Hormone; Follow-Up Studies; Food Microbiology; Forced Expiratory Volume; Forkhead Transcription Factors; Frontotemporal Dementia; G-Quadruplexes; Galactose; Gastroenteritis; Gastrointestinal Diseases; Gastrointestinal Microbiome; Gastrointestinal Neoplasms; Gastrointestinal Tract; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Genital Neoplasms, Female; Genome-Wide Association Study; Genome, Viral; Genomics; Genotype; Glucose; Glutathione; Glycerol; Gold; Graphite; GTPase-Activating Proteins; Heat-Shock Proteins; Heme Oxygenase-1; Hepacivirus; Hepatitis C; Hepatocytes; Histamine; Histocompatibility Antigens Class II; Hoarseness; Hospice and Palliative Care Nursing; Humans; Hydrogen; Hydrogen Peroxide; Hydrogen Sulfide; Hydroxybenzoates; Hydroxyl Radical; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperthermia, Induced; Hysteroscopy; Immunoassay; Indigo Carmine; Inflammation; Inflammatory Bowel Diseases; Insulin Resistance; Intensive Care Units; Interleukin-11; Interleukin-6; Interleukins; Iodine Radioisotopes; Iran; Iridium; Islets of Langerhans; Kinetics; Lactation; Lactobacillus; Lactobacillus plantarum; Lamins; Latin America; Lead; Lectins; Leukopenia; Ligands; Limit of Detection; Lipopolysaccharides; Lipoprotein Lipase; Liver; Liver Cirrhosis; Liver Neoplasms; Lolium; Luminescent Measurements; Luminol; Lung; Luteinizing Hormone; Macrophages; Magnetic Phenomena; Magnetic Resonance Imaging; Male; Malnutrition; Maltose; Manganese Compounds; Maternal Nutritional Physiological Phenomena; Melatonin; Metabolic Engineering; Metal Nanoparticles; Metallocenes; Metaplasia; Methicillin-Resistant Staphylococcus aureus; Methylation; Mevalonic Acid; Mexico; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microbial Sensitivity Tests; Microbiota; MicroRNAs; Milk; Mitomycin; Molecular Diagnostic Techniques; Molecular Docking Simulation; Monte Carlo Method; Moringa oleifera; Multiple Sclerosis; Muscle Strength; Muscle, Skeletal; Nanocomposites; Nanotubes, Carbon; Neoadjuvant Therapy; Neoplasms; Neurodegenerative Diseases; Neurotransmitter Agents; NF-E2-Related Factor 2; Nickel; Nitrogen Dioxide; Non-alcoholic Fatty Liver Disease; Nucleic Acid Amplification Techniques; Nucleic Acid Hybridization; Nucleocapsid Proteins; Nutritional Status; Obesity; Osteogenesis; Osteosarcoma; Oxidation-Reduction; Oxides; Oxygen; Oxyquinoline; Pain; Palliative Care; Pancreatic Neoplasms; Pandemics; Particulate Matter; Peroxidase; Peroxidases; Phagocytosis; Phaseolus; Photothermal Therapy; Point-of-Care Systems; Polyethyleneimine; Polymers; Polymorphism, Single Nucleotide; Polysomnography; Postoperative Complications; Pregnancy; Pregnant Women; Prenatal Exposure Delayed Effects; Prevalence; Printing, Three-Dimensional; Probability; Probiotics; Prognosis; Prophages; Prospective Studies; Proteomics; Proto-Oncogene Proteins; Pseudomonas aeruginosa; Pseudomonas putida; Pulmonary Disease, Chronic Obstructive; Pulmonary Embolism; Pyridines; Pyrroles; Quality of Life; Quinolones; Rabbits; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Receptors, Histamine; Receptors, Histamine H2; Recombinases; Rectal Neoplasms; Reperfusion Injury; Respiration; Respiratory Function Tests; Respiratory Rate; Respiratory Sounds; Retrospective Studies; rho GTP-Binding Proteins; Risk Assessment; Risk Factors; RNA; RNA, Messenger; RNA, Ribosomal, 16S; Robotic Surgical Procedures; Running; Rural Population; Saccharomyces cerevisiae; Salpingectomy; Sarcopenia; SARS-CoV-2; Seeds; Semen; Sensitivity and Specificity; Sepsis; Shock, Septic; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Skin Neoplasms; Sleep Apnea, Obstructive; Soil; Spain; Spectrum Analysis, Raman; Sperm Retrieval; Spermatozoa; Spirometry; Staphylococcus aureus; STAT3 Transcription Factor; Stereoisomerism; Sterilization, Tubal; Stroke Volume; Sulfadiazine; Sulfites; Superoxide Dismutase; Surface Plasmon Resonance; tau Proteins; Testis; Testosterone; Thioredoxin-Disulfide Reductase; Thyroid Neoplasms; Thyroidectomy; Trans-Activators; Transcription Factor AP-1; Treatment Outcome; Triazoles; Triclosan; Trifluridine; Tumor Microenvironment; Tumor Necrosis Factor-alpha; United States; Uracil; Vagina; Vegetables; Ventricular Function, Left; Ventricular Pressure; Vibrio cholerae; Vietnam; Virulence; Vital Capacity; Vitrification; Walking; Water; Water Pollutants, Radioactive; Whole Genome Sequencing; Wind; YAP-Signaling Proteins; Zeolites; Zinc Oxide | 2023 |
Consumption of quinolones in the community, European Union/European Economic Area, 1997-2017.
Topics: Anti-Bacterial Agents; Bacterial Infections; Drug Utilization; Europe; European Union; Humans; Outpatients; Quinolones | 2021 |
Prevention of infectious complications after prostate biopsy procedure.
Topics: Administration, Oral; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacteria; Bacterial Infections; Biopsy; Drug Resistance, Bacterial; Gastrointestinal Microbiome; Humans; Male; Postoperative Complications; Practice Guidelines as Topic; Prostate; Prostatic Neoplasms; Quinolones; Rectum | 2017 |
Fosfomycin vs. quinolone-based antibiotic prophylaxis for transrectal ultrasound-guided biopsy of the prostate: a systematic review and meta-analysis.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Fosfomycin; Humans; Image-Guided Biopsy; Male; Prostatic Neoplasms; Quinolones; Ultrasonography | 2018 |
Pregnancy Outcomes Following Exposure to Quinolone Antibiotics - a Systematic-Review and Meta-Analysis.
Topics: Abnormalities, Drug-Induced; Anti-Bacterial Agents; Bacterial Infections; Birth Weight; Female; Humans; Pregnancy; Pregnancy Complications; Pregnancy Trimester, First; Premature Birth; Quinolones; Stillbirth | 2018 |
Plasmid-mediated quinolone resistance--current knowledge and future perspectives.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Drug Resistance, Bacterial; Genes, Bacterial; Humans; Plasmids; Quinolones | 2013 |
Mechanism of quinolone action and resistance.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Bacterial Proteins; Drug Resistance, Bacterial; Humans; Quinolones | 2014 |
Renaissance of antibiotics against difficult infections: Focus on oritavancin and new ketolides and quinolones.
Topics: Anti-Bacterial Agents; Bacterial Infections; Drug Resistance, Bacterial; Glycopeptides; Humans; Lipoglycopeptides; Macrolides; Quinolones; Triazoles | 2014 |
Nemonoxacin: first global approval.
Topics: Anti-Bacterial Agents; Bacterial Infections; Diabetic Foot; Drug Approval; Humans; Pneumonia; Quinolones | 2014 |
Inhaled antibiotics beyond aminoglycosides, polymyxins and aztreonam: A systematic review.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Bronchiectasis; Cystic Fibrosis; Fosfomycin; Humans; Pneumonia, Ventilator-Associated; Quinolones; Respiratory Tract Infections; Treatment Outcome | 2015 |
Origins of the Quinolone Class of Antibacterials: An Expanded "Discovery Story".
Topics: Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Drug Discovery; History, 20th Century; History, 21st Century; Humans; Nalidixic Acid; Quinolones | 2015 |
The challenges of managing older patients with acute lymphoblastic leukemia.
Topics: Age Distribution; Aged; Antineoplastic Agents; Bacterial Infections; Female; Forecasting; Geriatric Assessment; Humans; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm, Residual; Patient Care Planning; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Quinolones; Randomized Controlled Trials as Topic; Renal Insufficiency; Sex Distribution; Survival Analysis; Transplantation, Autologous; United Kingdom | 2015 |
Mechanisms of drug resistance: quinolone resistance.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Bacterial Proteins; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Humans; Mutation; Quinolones | 2015 |
The Current Case of Quinolones: Synthetic Approaches and Antibacterial Activity.
Topics: Anti-Bacterial Agents; Bacterial Infections; Chloroquine; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Escherichia coli; Humans; Quinolones; Topoisomerase II Inhibitors | 2016 |
[Classification and prevalence of plasmid-mediated quinolone resistance qnr genes in China--A review].
Topics: Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Bacterial Proteins; China; Drug Resistance, Bacterial; Humans; Plasmids; Quinolones | 2016 |
Plasmid-mediated quinolone resistance: Two decades on.
Topics: Acetyltransferases; Anti-Bacterial Agents; Bacterial Infections; Bacterial Proteins; Chromosomes, Bacterial; Drug Resistance, Bacterial; Escherichia coli Proteins; Gene Expression Regulation, Bacterial; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Plasmids; Protein Isoforms; Quinolones; Treatment Failure | 2016 |
New agents in development for the treatment of bacterial infections.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Glycopeptides; Humans; Macrolides; Oxazolidinones; Quinolones | 2008 |
[Collateral damage of cephalosporins and quinolones and possibilities for control].
Topics: Acinetobacter; Bacterial Infections; beta-Lactam Resistance; beta-Lactamases; Cephalosporins; Clostridioides difficile; Delayed-Action Preparations; Drug Resistance, Microbial; Drug Resistance, Multiple, Bacterial; Enterococcus; Gram-Negative Bacteria; Humans; Klebsiella pneumoniae; Methicillin-Resistant Staphylococcus aureus; Pseudomonas aeruginosa; Quinolones; Vancomycin Resistance | 2009 |
New quinolone antibiotics: a survey of the literature from 2005 to 2010.
Topics: Animals; Anti-Bacterial Agents; Anti-HIV Agents; Antitubercular Agents; Bacterial Infections; Drug Discovery; Drug Evaluation, Preclinical; Humans; Quinolones; Structure-Activity Relationship | 2010 |
[Safety profile of antimicrobial agents].
Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Bacterial Infections; Convulsants; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Humans; Hypoglycemia; Kidney; Mice; Quinolones; Structure-Activity Relationship; Theophylline | 2011 |
Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacteremia; Bacterial Infections; Cause of Death; Drug Resistance, Bacterial; Fever; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Neoplasms; Neutropenia; Quinolones; Randomized Controlled Trials as Topic; Trimethoprim, Sulfamethoxazole Drug Combination | 2012 |
Advances in antibiotic measurement.
Topics: Aminoglycosides; Anti-Bacterial Agents; Antitubercular Agents; Bacteria; Bacterial Infections; Cephalosporins; Chloramphenicol; Chromatography; Humans; Immunoassay; Macrolides; Penicillins; Quinolones; Sulfonamides; Vancomycin | 2012 |
Transferable mechanisms of quinolone resistance.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Drug Resistance, Bacterial; Gene Transfer, Horizontal; Genes, Bacterial; Humans; Phylogeny; Plasmids; Quinolones | 2012 |
Development of the quinolones.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Humans; Quinolones; Structure-Activity Relationship | 2003 |
[Positioning of various antibacterial agents and their appropriate usage in the era of multiple drug-resistant bacteria. 4. Quinolones].
Topics: Anti-Infective Agents; Bacterial Infections; Drug Resistance, Multiple, Bacterial; Humans; Quinolones | 2003 |
Quinolones in dermatology.
Topics: Anti-Infective Agents; Area Under Curve; Bacterial Infections; Biological Availability; Ciprofloxacin; Fluoroquinolones; Humans; Intestinal Absorption; Microbial Sensitivity Tests; Nalidixic Acid; Quinolones; Skin Diseases; Structure-Activity Relationship | 2004 |
Quinolones in 2005: an update.
Topics: Anti-Infective Agents; Bacteria; Bacterial Infections; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Tests; Quinolones; Structure-Activity Relationship | 2005 |
Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Neoplasms; Neutropenia; Quinolones; Randomized Controlled Trials as Topic; Trimethoprim, Sulfamethoxazole Drug Combination | 2005 |
Prulifloxacin: a new antibacterial fluoroquinolone.
Topics: Anti-Bacterial Agents; Bacterial Infections; Clinical Trials as Topic; Community-Acquired Infections; Cross Infection; Dioxolanes; Drug Resistance, Bacterial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Piperazines; Quinolones; Respiratory Tract Infections; Treatment Outcome | 2006 |
Prevention and treatment of infections in patients with cirrhosis.
Topics: Anti-Bacterial Agents; Bacterial Infections; Humans; Liver Cirrhosis; Peritonitis; Quinolones | 2007 |
[Quinolone antibacterials--oral preparation].
Topics: Administration, Oral; Anti-Bacterial Agents; Bacterial Infections; Enteritis; Humans; Otorhinolaryngologic Diseases; Quinolones; Respiratory Tract Infections; Urinary Tract Infections | 2007 |
[Bacterial internalization and intracellular activity of quinolones and macrolides].
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Humans; Immunoglobulin A; Intracellular Space; Macrolides; Quinolones | 2007 |
Antibacterial prophylaxis in neutropenic patients.
Topics: Adult; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Child; Humans; Neutropenia; Quinolones | 2007 |
[Usefulness of pharmacokinetic and pharmacodynamic parameters fro establishing the optimal dosage of antibacterials].
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacterial Infections; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Lactams; Quinolones | 1995 |
Empiric therapy for infections in the febrile, neutropenic, compromised host.
Topics: Algorithms; Aminoglycosides; Anti-Bacterial Agents; Bacterial Infections; Clinical Trials as Topic; Drug Therapy, Combination; Fever of Unknown Origin; Humans; Immunocompromised Host; Lactams; Mycoses; Neutropenia; Quinolones; Sulfamethoxazole; Time Factors; Trimethoprim; Vancomycin; Virus Diseases | 1995 |
[Significant role of newer quinolone antimicrobials in respiratory tract infection: focused on sparfloxacin].
Topics: Anti-Infective Agents; Bacterial Infections; Fluoroquinolones; Humans; Photosensitivity Disorders; Quinolones; Respiratory Tract Infections | 1994 |
Quinolones: a practical review of clinical uses, dosing considerations, and drug interactions.
Topics: Anti-Infective Agents; Bacterial Infections; Drug Interactions; Fluoroquinolones; Humans; Intestinal Absorption; Liver; Quinolones | 1996 |
Possible role for the new fluoroquinolones (levofloxacin, grepafloxacin, trovafloxacin, clinafloxacin, sparfloxacin, and DU-6859a) in the treatment of anaerobic infections: review of current information on efficacy and safety.
Topics: Anti-Infective Agents; Bacteria, Anaerobic; Bacterial Infections; Fluoroquinolones; Humans; Levofloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolones; Safety; Syndrome | 1996 |
Grepafloxacin.
Topics: Anti-Infective Agents; Bacterial Infections; Fluoroquinolones; Humans; Multicenter Studies as Topic; Piperazines; Quinolones; Randomized Controlled Trials as Topic | 1997 |
Spontaneous bacterial peritonitis. Detection, treatment and prophylaxis in patients with liver cirrhosis.
Topics: Antibiotic Prophylaxis; Ascites; Ascitic Fluid; Bacteria; Bacterial Infections; Cephalosporins; Drug Therapy, Combination; Humans; Liver Cirrhosis; Peritonitis; Prognosis; Quinolones | 1997 |
Antibacterial activity of grepafloxacin.
Topics: Anti-Infective Agents; Bacterial Infections; Fluoroquinolones; Humans; Piperazines; Quinolones | 1997 |
Safety profile of grepafloxacin compared with other fluoroquinolones.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Evaluation; Fluoroquinolones; Humans; Piperazines; Quinolones | 1997 |
Grepafloxacin in respiratory tract infections: are we ready to accept a quinolone for empirical treatment?
Topics: Anti-Infective Agents; Bacterial Infections; Drug Resistance, Microbial; Fluoroquinolones; Humans; Piperazines; Quinolones; Respiratory Tract Infections | 1997 |
[Antibiotic prophylaxis of ascitic fluid infection].
Topics: Antibiotic Prophylaxis; Ascitic Fluid; Bacterial Infections; Clinical Trials as Topic; Humans; Quinolones; Risk Factors | 1998 |
[A broad-spectrum antimicrobial preparation--lomefloxacin (Maxaquin): the results of 10 years of its use in the clinics of Russia].
Topics: Anti-Infective Agents; Anti-Infective Agents, Urinary; Antitubercular Agents; Bacterial Infections; Clinical Trials as Topic; Dose-Response Relationship, Drug; Fluoroquinolones; Humans; Quinolones; Russia | 2000 |
Drug utilization reviews of oral quinolone, cephalosporin, and macrolide use in nonacute care: a systematic review.
Topics: Bacterial Infections; Cephalosporins; Cost-Benefit Analysis; Drug Prescriptions; Drug Therapy; Drug Utilization Review; Humans; Macrolides; North America; Quinolones | 1999 |
Antibacterial agents (oxazolidinones, quinolones, macrolides and new agents): patent highlights June to December 2000.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Humans; Macrolides; Oxazoles; Patents as Topic; Quinolones | 2001 |
[How do we use quinolones? Indications from the viewpoint of clinical microbiology].
Topics: Animals; Bacterial Infections; Humans; Quinolones | 2001 |
[How are quinolones used in clinical practice? Gyrase antagonists from the viewpoint of the hospital pharmacist].
Topics: Anti-Infective Agents; Bacterial Infections; Enzyme Inhibitors; Humans; Pharmacy Service, Hospital; Quinolones; Topoisomerase II Inhibitors | 2001 |
T-3811. Toyama/Bristol-Myers Squibb.
Topics: Animals; Anti-Infective Agents; Bacteria; Bacterial Infections; Clinical Trials, Phase I as Topic; Humans; Indoles; Isoindoles; Quinolones; Structure-Activity Relationship | 2001 |
Infection in the elderly: studies with lomefloxacin.
Topics: Aged; Aging; Anti-Infective Agents; Bacterial Infections; Bronchitis; Female; Fluoroquinolones; Humans; Male; Meta-Analysis as Topic; Middle Aged; Multicenter Studies as Topic; Premedication; Quinolones; Randomized Controlled Trials as Topic; Urinary Tract Infections | 1992 |
The U.S. clinical experience with lomefloxacin, a new once-daily fluoroquinolone.
Topics: Anti-Infective Agents; Bacterial Infections; Bronchitis; Fluoroquinolones; Humans; Meta-Analysis as Topic; Premedication; Quinolones; Randomized Controlled Trials as Topic; United States; Urinary Tract Infections | 1992 |
Lomefloxacin and temafloxacin: two new fluoroquinolone antimicrobials.
Topics: Anti-Infective Agents; Bacteria; Bacterial Infections; Drug Interactions; Drug Resistance, Microbial; Fluoroquinolones; Humans; Quinolones | 1992 |
Sparfloxacin and other new fluoroquinolones.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Enterobacteriaceae; Fluoroquinolones; Gram-Positive Bacteria; Humans; Mycoplasma; Quinolones | 1992 |
[Fluoroquinolones].
Topics: Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Cattle; DNA Topoisomerases, Type II; DNA, Bacterial; Humans; In Vitro Techniques; Quinolones | 1991 |
The role of quinolones in the treatment of chronic bacterial prostatitis.
Topics: Bacterial Infections; Body Fluids; Chronic Disease; Clinical Trials as Topic; Female; Humans; Male; Prostatitis; Quinolones | 1991 |
[Review [new antimicrobial agent series XLI]: lomefloxacin].
Topics: Animals; Anti-Infective Agents; Bacteria; Bacterial Infections; Drug Evaluation; Drug Resistance, Microbial; Fluoroquinolones; Humans; Mice; Quinolones; Rats; Tissue Distribution | 1991 |
Systemic management of cutaneous bacterial infections.
Topics: Anti-Infective Agents; Bacterial Infections; Fluoroquinolones; Humans; Quinolones; Skin Diseases, Infectious | 1991 |
Temafloxacin: an overview.
Topics: Anti-Infective Agents; Bacterial Infections; Fluoroquinolones; Humans; Male; Microbial Sensitivity Tests; Prostatitis; Quinolones; Respiratory Tract Infections; Sexually Transmitted Diseases, Bacterial; Skin Diseases, Infectious; Urinary Tract Infections | 1991 |
Lomefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
Topics: Animals; Anti-Infective Agents; Bacteria; Bacterial Infections; Drug Interactions; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Quinolones | 1991 |
[Gyrase inhibitors, a new class of therapeutic drugs].
Topics: 4-Quinolones; Animals; Anti-Infective Agents; Bacterial Infections; Chronic Disease; Drug Resistance, Microbial; Enrofloxacin; Fluoroquinolones; Quinolones; Respiratory Tract Diseases | 1991 |
The febrile neutropenic patient: newer options for empirical therapy.
Topics: Agranulocytosis; Anti-Bacterial Agents; Aztreonam; Bacterial Infections; Carbapenems; Cephalosporins; Drug Resistance, Microbial; Drug Therapy, Combination; Fever; Humans; Neutropenia; Quinolones | 1990 |
Chemoprophylaxis of gram-negative infections in neutropenic patients.
Topics: Agranulocytosis; Anti-Bacterial Agents; Bacterial Infections; Drug Therapy, Combination; Gram-Negative Bacteria; Humans; Neutropenia; Quinolones; Trimethoprim, Sulfamethoxazole Drug Combination | 1990 |
Acute and chronic bacterial prostatitis: a review of treatment approaches.
Topics: Acute Disease; Bacterial Infections; Chronic Disease; Humans; Male; Prostatitis; Quinolones | 1990 |
Carbapenems, monobactams and quinolones.
Topics: Aztreonam; Bacterial Infections; Humans; Imipenem; Quinolones | 1989 |
21 trial(s) available for carbostyril and Bacterial Infections
| Article | Year |
|---|---|
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosphate; Adsorption; Adult; Africa, Eastern; Aged; Air Pollutants; Air Pollution; Air Pollution, Indoor; Alcohol Drinking; Allergens; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Anti-Bacterial Agents; Antibodies; Antibodies, Immobilized; Antigen Presentation; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Aptamers, Nucleotide; Asthma; Asthma, Exercise-Induced; Atrophy; Autophagy; Azoospermia; Bacillus cereus; Bacterial Infections; Beclin-1; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biofouling; Biological Monitoring; Biomarkers; Biomarkers, Tumor; Biosensing Techniques; Blastocyst; Bone Neoplasms; Bone Regeneration; Bronchoconstriction; Burkitt Lymphoma; C9orf72 Protein; Campylobacter; Campylobacter Infections; Campylobacter jejuni; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Cardiomyopathies; Caregivers; Carmine; Case-Control Studies; Catalysis; Cattle; Cause of Death; CCAAT-Enhancer-Binding Protein-alpha; CD8-Positive T-Lymphocytes; Cefepime; Cell Differentiation; Cell Line, Tumor; Cell Nucleus; Cell Transdifferentiation; Chelating Agents; Chemical and Drug Induced Liver Injury, Chronic; Chemoradiotherapy, Adjuvant; Child; Child, Preschool; China; Chlorquinaldol; Cholangiocarcinoma; Cholera; Chromatin; Clinical Trials as Topic; Cognitive Dysfunction; Cohort Studies; Colonic Neoplasms; Colorectal Neoplasms; Colorimetry; Cooking; Coordination Complexes; COVID-19; Creatinine; CRISPR-Cas Systems; Critical Care; Critical Illness; Cross-Sectional Studies; Cryopreservation; Cryoprotective Agents; Cysteine; Cytokines; Device Removal; Diet; Diet, High-Fat; Diet, Mediterranean; Dietary Supplements; Dimethyl Sulfoxide; Dipeptides; Disease Models, Animal; Dithiothreitol; DNA; DNA Repeat Expansion; DNA, Bacterial; DNA, Complementary; Dopamine; Electrochemical Techniques; Electrodes; Endocannabinoids; Environmental Exposure; Environmental Monitoring; Environmental Pollutants; Enzyme-Linked Immunosorbent Assay; Erlotinib Hydrochloride; Escherichia coli; Escherichia coli O157; Esophageal Neoplasms; Esophagitis, Peptic; Ethylene Glycol; Europium; Exanthema; Fallopian Tubes; Feces; Female; Fertilization in Vitro; Fluoresceins; Fluorescent Dyes; Follicle Stimulating Hormone; Follow-Up Studies; Food Microbiology; Forced Expiratory Volume; Forkhead Transcription Factors; Frontotemporal Dementia; G-Quadruplexes; Galactose; Gastroenteritis; Gastrointestinal Diseases; Gastrointestinal Microbiome; Gastrointestinal Neoplasms; Gastrointestinal Tract; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Genital Neoplasms, Female; Genome-Wide Association Study; Genome, Viral; Genomics; Genotype; Glucose; Glutathione; Glycerol; Gold; Graphite; GTPase-Activating Proteins; Heat-Shock Proteins; Heme Oxygenase-1; Hepacivirus; Hepatitis C; Hepatocytes; Histamine; Histocompatibility Antigens Class II; Hoarseness; Hospice and Palliative Care Nursing; Humans; Hydrogen; Hydrogen Peroxide; Hydrogen Sulfide; Hydroxybenzoates; Hydroxyl Radical; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperthermia, Induced; Hysteroscopy; Immunoassay; Indigo Carmine; Inflammation; Inflammatory Bowel Diseases; Insulin Resistance; Intensive Care Units; Interleukin-11; Interleukin-6; Interleukins; Iodine Radioisotopes; Iran; Iridium; Islets of Langerhans; Kinetics; Lactation; Lactobacillus; Lactobacillus plantarum; Lamins; Latin America; Lead; Lectins; Leukopenia; Ligands; Limit of Detection; Lipopolysaccharides; Lipoprotein Lipase; Liver; Liver Cirrhosis; Liver Neoplasms; Lolium; Luminescent Measurements; Luminol; Lung; Luteinizing Hormone; Macrophages; Magnetic Phenomena; Magnetic Resonance Imaging; Male; Malnutrition; Maltose; Manganese Compounds; Maternal Nutritional Physiological Phenomena; Melatonin; Metabolic Engineering; Metal Nanoparticles; Metallocenes; Metaplasia; Methicillin-Resistant Staphylococcus aureus; Methylation; Mevalonic Acid; Mexico; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microbial Sensitivity Tests; Microbiota; MicroRNAs; Milk; Mitomycin; Molecular Diagnostic Techniques; Molecular Docking Simulation; Monte Carlo Method; Moringa oleifera; Multiple Sclerosis; Muscle Strength; Muscle, Skeletal; Nanocomposites; Nanotubes, Carbon; Neoadjuvant Therapy; Neoplasms; Neurodegenerative Diseases; Neurotransmitter Agents; NF-E2-Related Factor 2; Nickel; Nitrogen Dioxide; Non-alcoholic Fatty Liver Disease; Nucleic Acid Amplification Techniques; Nucleic Acid Hybridization; Nucleocapsid Proteins; Nutritional Status; Obesity; Osteogenesis; Osteosarcoma; Oxidation-Reduction; Oxides; Oxygen; Oxyquinoline; Pain; Palliative Care; Pancreatic Neoplasms; Pandemics; Particulate Matter; Peroxidase; Peroxidases; Phagocytosis; Phaseolus; Photothermal Therapy; Point-of-Care Systems; Polyethyleneimine; Polymers; Polymorphism, Single Nucleotide; Polysomnography; Postoperative Complications; Pregnancy; Pregnant Women; Prenatal Exposure Delayed Effects; Prevalence; Printing, Three-Dimensional; Probability; Probiotics; Prognosis; Prophages; Prospective Studies; Proteomics; Proto-Oncogene Proteins; Pseudomonas aeruginosa; Pseudomonas putida; Pulmonary Disease, Chronic Obstructive; Pulmonary Embolism; Pyridines; Pyrroles; Quality of Life; Quinolones; Rabbits; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Receptors, Histamine; Receptors, Histamine H2; Recombinases; Rectal Neoplasms; Reperfusion Injury; Respiration; Respiratory Function Tests; Respiratory Rate; Respiratory Sounds; Retrospective Studies; rho GTP-Binding Proteins; Risk Assessment; Risk Factors; RNA; RNA, Messenger; RNA, Ribosomal, 16S; Robotic Surgical Procedures; Running; Rural Population; Saccharomyces cerevisiae; Salpingectomy; Sarcopenia; SARS-CoV-2; Seeds; Semen; Sensitivity and Specificity; Sepsis; Shock, Septic; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Skin Neoplasms; Sleep Apnea, Obstructive; Soil; Spain; Spectrum Analysis, Raman; Sperm Retrieval; Spermatozoa; Spirometry; Staphylococcus aureus; STAT3 Transcription Factor; Stereoisomerism; Sterilization, Tubal; Stroke Volume; Sulfadiazine; Sulfites; Superoxide Dismutase; Surface Plasmon Resonance; tau Proteins; Testis; Testosterone; Thioredoxin-Disulfide Reductase; Thyroid Neoplasms; Thyroidectomy; Trans-Activators; Transcription Factor AP-1; Treatment Outcome; Triazoles; Triclosan; Trifluridine; Tumor Microenvironment; Tumor Necrosis Factor-alpha; United States; Uracil; Vagina; Vegetables; Ventricular Function, Left; Ventricular Pressure; Vibrio cholerae; Vietnam; Virulence; Vital Capacity; Vitrification; Walking; Water; Water Pollutants, Radioactive; Whole Genome Sequencing; Wind; YAP-Signaling Proteins; Zeolites; Zinc Oxide | 2023 |
Serenoa repens extract additionally to quinolones in the treatment of chronic bacterial prostatitis. The preliminary results of a long term observational study.
Topics: Adult; Bacterial Infections; Chronic Disease; Combined Modality Therapy; Humans; Male; Middle Aged; Phytotherapy; Plant Extracts; Prospective Studies; Prostatitis; Quinolones; Serenoa; Time Factors | 2013 |
Pharmacokinetics, stability, and retrospective analysis of use of an oral gel formulation of the bovine injectable enrofloxacin in horses.
Topics: Absorption; Administration, Oral; Animals; Anti-Infective Agents; Antineoplastic Agents; Area Under Curve; Bacterial Infections; Biological Availability; Cross-Over Studies; Enrofloxacin; Female; Fluoroquinolones; Gels; Horse Diseases; Horses; Male; Quinolones; Retrospective Studies; Temperature; Treatment Outcome | 2004 |
The impact of an intensive antimicrobial control program in a Taiwanese medical center.
Topics: Adult; Aged; Aminoglycosides; Anti-Infective Agents; Bacterial Infections; Cephalosporins; Cross Infection; Drug Costs; Drug Resistance, Bacterial; Drug Utilization Review; Economics, Hospital; Erythromycin; Female; Glycopeptides; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Penicillins; Quinolones; Taiwan; Tetracyclines; Time Factors; Treatment Outcome | 2006 |
[Re-examination of the criteria for clinical evaluation on bacterial prostatitis--analysis of the data of the clinical study of temafloxacin].
Topics: Acute Disease; Adolescent; Adult; Aged; Anti-Infective Agents; Bacterial Infections; Chronic Disease; Fluoroquinolones; Humans; Male; Middle Aged; Prostatitis; Quinolones | 1994 |
[The dose-response study of sparfloxacin against skin and soft tissue structure infections in the field of surgery].
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bacteria; Bacterial Infections; Connective Tissue Diseases; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Female; Fluoroquinolones; Humans; Male; Middle Aged; Quinolones; Skin Diseases, Infectious | 1993 |
[Experimental and clinical studies of temafloxacin in the field of obstetrics and gynecology].
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Infective Agents; Bacteria; Bacterial Infections; Female; Fluoroquinolones; Genital Diseases, Female; Genitalia, Female; Humans; Middle Aged; Quinolones | 1993 |
NM441: penetration into gynaecological tissues and in vitro activity against clinical isolates from obstetric and gynaecological patients.
Topics: Administration, Oral; Anti-Infective Agents; Bacteria; Bacterial Infections; Dioxolanes; Female; Fluoroquinolones; Genital Diseases, Female; Genitalia, Female; Humans; Microbial Sensitivity Tests; Piperazines; Pregnancy; Quinolones | 1995 |
Initial clinical experience with clinafloxacin in the treatment of serious infections.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Bacterial Infections; Child; Ciprofloxacin; Drug Resistance, Multiple; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Middle Aged; Quinolones | 1995 |
Prophylactic antibiotics in renal transplantation.
Topics: 4-Quinolones; Anti-Infective Agents; Antibiotic Prophylaxis; Bacterial Infections; Cephalothin; Fluoroquinolones; Humans; Kidney Transplantation; Longitudinal Studies; Pefloxacin; Prospective Studies; Quinolones; Trimethoprim, Sulfamethoxazole Drug Combination | 1996 |
[Clinical efficacy of lomefloxacin for associated infection in patients with hematological diseases].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bacterial Infections; Female; Fluoroquinolones; Hematologic Diseases; Humans; Male; Middle Aged; Quinolones; Respiratory Tract Infections; Urinary Tract Infections | 1997 |
Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Analysis of Variance; Anti-Infective Agents; Bacteria; Bacterial Infections; Bronchitis; Chronic Disease; Dose-Response Relationship, Drug; Female; Fluoroquinolones; Humans; Male; Middle Aged; Models, Biological; Piperazines; Quinolones; Time Factors | 1997 |
Randomized, double-blind study of grepafloxacin versus amoxycillin in patients with acute bacterial exacerbations of chronic bronchitis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Infective Agents; Bacteria; Bacterial Infections; Bronchitis; Chronic Disease; Double-Blind Method; Female; Fluoroquinolones; Hematologic Tests; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Penicillins; Piperazines; Quinolones; Treatment Outcome | 1997 |
Effectiveness of short-course therapy (5 days) with grepafloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis.
Topics: Acute Disease; Adult; Aged; Anti-Infective Agents; Bacterial Infections; Bronchitis; Chronic Disease; Double-Blind Method; Drug Administration Schedule; Female; Fluoroquinolones; Humans; Male; Middle Aged; Piperazines; Quinolones | 1999 |
Assessment of the UTI criteria for bacterial prostatitis in Japan.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Anti-Infective Agents; Bacterial Infections; Chronic Disease; Fluoroquinolones; Humans; Male; Middle Aged; Prostatitis; Quinolones; Treatment Outcome | 1992 |
An open multicentre study on the efficacy and safety of rufloxacin in patients with chronic bacterial prostatitis.
Topics: Adult; Anti-Infective Agents; Bacterial Infections; Chronic Disease; Fluoroquinolones; Humans; Male; Middle Aged; Prostatitis; Quinolones | 1991 |
Systemic antimicrobial therapy in skin and skin structure infections: comparison of temafloxacin and ciprofloxacin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Double-Blind Method; Female; Fluoroquinolones; Humans; Male; Middle Aged; Quinolones; Skin Diseases, Infectious | 1991 |
Treatment of chronic bacterial prostatitis with temafloxacin.
Topics: Adult; Aged; Anti-Infective Agents; Bacterial Infections; Double-Blind Method; Fluoroquinolones; Humans; Male; Middle Aged; Prostatitis; Quinolones | 1991 |
Acute and chronic bacterial prostatitis: a review of treatment approaches.
Topics: Acute Disease; Bacterial Infections; Chronic Disease; Humans; Male; Prostatitis; Quinolones | 1990 |
[Comparison of clinical efficacy of lomefloxacin (LFLX, NY-198) and pipemidic acid (PPA) in the treatment of infectious enteritis by a double-blind method. The Japan Research Committee of Lomefloxacin Research Group Enteritis].
Topics: 4-Quinolones; Adolescent; Adult; Aged; Anti-Infective Agents; Bacterial Infections; Double-Blind Method; Drug Evaluation; Enteritis; Female; Fluoroquinolones; Humans; Japan; Male; Middle Aged; Multicenter Studies as Topic; Nicotinic Acids; Pipemidic Acid; Quinolones | 1989 |
Unsuccessful treatment of non-gonococcal urethritis with rosoxacin provides information on the aetiology of the disease.
Topics: 4-Quinolones; Anti-Bacterial Agents; Bacterial Infections; Chlamydia trachomatis; Clinical Trials as Topic; Drug Administration Schedule; Humans; Male; Microbial Sensitivity Tests; Quinolines; Quinolones; Random Allocation; Tetracyclines; Ureaplasma; Urethritis | 1985 |
123 other study(ies) available for carbostyril and Bacterial Infections
| Article | Year |
|---|---|
Bacterial infections in patients with acute variceal bleeding in the era of antibiotic prophylaxis.
Topics: Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Cephalosporins; Esophageal and Gastric Varices; Female; Hemorrhage; Humans; Incidence; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Quinolones; Risk Factors | 2021 |
The effectiveness of rotating versus single course antibiotics for small intestinal bacterial overgrowth.
Topics: Adult; Aged; Anti-Bacterial Agents; Azoles; Bacterial Infections; Breath Tests; Drug Administration Schedule; Female; Humans; Intestine, Small; Male; Middle Aged; Quality of Life; Quinolones; Retrospective Studies | 2021 |
Understanding and Sensitizing Density-Dependent Persistence to Quinolone Antibiotics.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Carbon; Cell Respiration; Drug Resistance, Bacterial; Microbial Sensitivity Tests; Oxidative Phosphorylation; Oxygen; Quinolones | 2017 |
Enumerating the economic cost of antimicrobial resistance per antibiotic consumed to inform the evaluation of interventions affecting their use.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Carbapenems; Drug Resistance, Bacterial; Drug Utilization; Humans; Macrolides; Quinolones; Thailand; United States | 2018 |
Prophylaxis of spontaneous bacterial peritonitis: Is there still room for quinolones?
Topics: Bacterial Infections; Humans; Liver Cirrhosis; Peritonitis; Quinolones | 2019 |
Reply to: "Prophylaxis of spontaneous bacterial peritonitis: is there still room for quinolones?"
Topics: Bacterial Infections; Humans; Liver Cirrhosis; Peritonitis; Quinolones | 2019 |
Evidence of Significant Ceftriaxone and Quinolone Resistance in Cirrhotics with Spontaneous Bacterial Peritonitis.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Boston; Ceftriaxone; Drug Resistance, Bacterial; Female; Humans; Length of Stay; Liver Cirrhosis; Male; Middle Aged; Peritonitis; Quinolones; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2019 |
Quinolone and Multidrug Resistance Predicts Failure of Antibiotic Prophylaxis of Spontaneous Bacterial Peritonitis.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Humans; Liver Cirrhosis; Peritonitis; Quinolones | 2020 |
Synthesis and study of 1-ethyl-3-carbohydrazide and 3-[1-oxo-2-hydrazino-3-{p-toluenesulfon}]quinolone derivatives against bacterial infections.
Topics: Anti-Bacterial Agents; Bacterial Infections; Dose-Response Relationship, Drug; Escherichia coli; Hydrazines; Microbial Sensitivity Tests; Molecular Structure; Pseudomonas aeruginosa; Quinolones; Salmonella typhi; Staphylococcus aureus; Structure-Activity Relationship | 2013 |
Optical control of antibacterial activity.
Topics: Anti-Bacterial Agents; Azo Compounds; Bacteria; Bacterial Infections; Drug Design; Escherichia coli; Isomerism; Light; Microbial Sensitivity Tests; Photochemical Processes; Quinolones | 2013 |
Ceftriaxone and infection in first episode adolescent psychosis.
Topics: Adolescent; Anti-Bacterial Agents; Aripiprazole; Bacterial Infections; Ceftriaxone; Humans; Male; Piperazines; Psychotic Disorders; Quinolones | 2013 |
Ozenoxacin: a review of absorption, dermal exposure and toxicity, tolerability and safety studies.
Topics: Aminopyridines; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Drug Evaluation; Drug Tolerance; Humans; Quinolones; Skin | 2014 |
Topological Model for the Search of New Antibacterial Drugs. 158 Theoretical Candidates.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Computer Simulation; Computer-Aided Design; Discriminant Analysis; Drug Design; Humans; Models, Biological; Quantitative Structure-Activity Relationship; Quinolones | 2015 |
Clinical importance of the antibiotic regimen in transrectal ultrasound-guided biopsy: quinolone versus cephalosporin.
Topics: Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Cephalosporins; Humans; Image-Guided Biopsy; Male; Middle Aged; Postoperative Complications; Prostate; Quinolones; Retrospective Studies; Ultrasonography, Interventional | 2016 |
Broad-spectrum antibiotics in Norwegian hospitals.
Topics: Anti-Bacterial Agents; Bacterial Infections; Carbapenems; Cephalosporins; Cross Infection; Cross-Sectional Studies; Drug Prescriptions; Drug Resistance, Bacterial; Drug Utilization Review; Guideline Adherence; Hospitals; Humans; Norway; Piperacillin; Quinolones; Respiratory Tract Infections | 2017 |
First detection of plasmid-mediated quinolone resistance in the community setting and in hospitalized patients in Switzerland.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Community-Acquired Infections; Cross Infection; DNA, Bacterial; Drug Resistance, Bacterial; Female; Humans; Male; Plasmids; Quinolones; Switzerland | 2008 |
Prevalence of quinolone-resistant urinary tract infections in Comanche County Memorial Hospital.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Infections; Drug Resistance, Bacterial; Humans; Middle Aged; Oklahoma; Prevalence; Quinolones; Urinary Tract Infections | 2008 |
[Quinolones].
Topics: Bacterial Infections; Humans; Quinolones | 2009 |
Synthesis, antimicrobial, and mosquito larvicidal activity of 1-aryl-4-methyl-3,6-bis-(5-methylisoxazol-3-yl)-2-thioxo-2,3,6,10b-tetrahydro-1H-pyrimido[5,4-c]quinolin-5-ones.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antifungal Agents; Bacteria; Bacterial Infections; Culex; Culicidae; Fungi; Humans; Isoxazoles; Larva; Microbial Sensitivity Tests; Mycoses; Pyrimidines; Quinolones | 2010 |
European Surveillance of Antimicrobial Consumption (ESAC): outpatient antibiotic use in Europe (1997-2009).
Topics: Ambulatory Care; Anti-Bacterial Agents; Bacterial Infections; Drug Utilization; Europe; Humans; Outpatients; Penicillins; Pharmacoepidemiology; Quinolones; Seasons; Statistics as Topic; Trimethoprim | 2011 |
European Surveillance of Antimicrobial Consumption (ESAC): outpatient quinolone use in Europe (1997-2009).
Topics: Ambulatory Care; Anti-Bacterial Agents; Bacterial Infections; Drug Utilization; Europe; Humans; Outpatients; Pharmacoepidemiology; Quinolones; Respiratory Tract Infections; Seasons; Statistics as Topic | 2011 |
Regional variations in quinolone use in France and associated factors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; Child; Child, Preschool; Drug Utilization; Female; France; Geography; Humans; Infant; Infant, Newborn; Male; Middle Aged; Quinolones; Young Adult | 2012 |
Quinolones and where they fit in today's environment of multidrug-resistant bugs.
Topics: Anti-Bacterial Agents; Bacterial Infections; Drug Resistance, Multiple, Bacterial; Humans; Quinolones; Urinary Tract Infections | 2012 |
Pharmacokinetics of marbofloxacin in mature horses after single intravenous and intramuscular administration.
Topics: Absorption; Animals; Anti-Infective Agents; Bacteria; Bacterial Infections; Biological Availability; Chromatography, High Pressure Liquid; Colony Count, Microbial; Dose-Response Relationship, Drug; Female; Fluoroquinolones; Horse Diseases; Horses; Injections, Intramuscular; Injections, Intravenous; Male; Metabolic Clearance Rate; Quinolones; Reference Values; Tissue Distribution; Treatment Outcome | 2002 |
Pharmacokinetics of marbofloxacin in horses.
Topics: Administration, Oral; Animals; Anti-Infective Agents; Bacteria; Bacterial Infections; Colony Count, Microbial; Cross-Over Studies; Dose-Response Relationship, Drug; Female; Fluoroquinolones; Horse Diseases; Horses; Injections, Intravenous; Injections, Subcutaneous; Intestinal Absorption; Male; Metabolic Clearance Rate; Microbial Sensitivity Tests; Nutritive Value; Quinolones; Random Allocation; Treatment Outcome | 2002 |
Activities of garenoxacin (BMS-284756) and other agents against anaerobic clinical isolates.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacteria, Anaerobic; Bacterial Infections; Chicago; Culture Media; Fluoroquinolones; Indoles; Microbial Sensitivity Tests; Quinolones | 2003 |
Comparative study of the in vitro activity of a new fluoroquinolone, ABT-492.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacteria; Bacterial Infections; Chlamydia trachomatis; Chlamydophila pneumoniae; Ciprofloxacin; Erythromycin; Fluoroquinolones; Humans; Ketolides; Macrolides; Microbial Sensitivity Tests; Quinolones | 2004 |
Quinolone safety and efficacy more important than potency.
Topics: Adult; Bacterial Infections; Community-Acquired Infections; Dose-Response Relationship, Drug; Female; Humans; Pneumonia; Quinolones | 2004 |
Seven years survey of susceptibility to marbofloxacin of bovine pathogenic strains from eight European countries.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Cattle; Cattle Diseases; Drug Resistance, Bacterial; Enteritis; Escherichia coli; Europe; Fluoroquinolones; Haemophilus somnus; Mannheimia haemolytica; Mastitis, Bovine; Microbial Sensitivity Tests; Pasteurella multocida; Quinolones; Respiratory Tract Infections; Salmonella; Staphylococcus aureus; Streptococcus | 2004 |
In vitro evaluation of lomefloxacin (NY-198 or SC-47111), a new difluoro-quinolone.
Topics: Anti-Infective Agents; Bacteria; Bacterial Infections; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Quinolones | 1989 |
In vitro antimicrobial activity of lomefloxacin against staphylococci, enterococci, and Enterobacteriaceae.
Topics: Anti-Infective Agents; Bacterial Infections; Enterobacteriaceae; Enterococcus; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Quinolones; Staphylococcus | 1989 |
Comparison of the antibacterial activity of lomefloxacin with that of other antibiotic/chemotherapeutic agents.
Topics: Anti-Bacterial Agents; Bacterial Infections; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Quinolones | 1989 |
Clinical impact of in vitro data with newer quinolones.
Topics: Antacids; Anti-Bacterial Agents; Bacterial Infections; Drug Interactions; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Quinolones | 1989 |
Are the quinolones realising their clinical potential?
Topics: Anti-Bacterial Agents; Bacterial Infections; Gram-Negative Bacterial Infections; Humans; Penicillins; Quinolones; Tissue Distribution; Urinary Tract Infections | 1989 |
The use of quinolones in the treatment of acute bacterial diarrhea: a comparative therapeutic trial.
Topics: Acute Disease; Adolescent; Anti-Infective Agents; Bacteria; Bacterial Infections; Chloramphenicol; Diarrhea; Feces; Female; Humans; Male; Norfloxacin; Quinolones; Randomized Controlled Trials as Topic; Tetracycline; Trimethoprim, Sulfamethoxazole Drug Combination | 1989 |
Antibacterial prophylaxis in patients with cancer and neutropenia.
Topics: Adult; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Drug Resistance, Bacterial; Fever; Humans; Neoplasms; Neutropenia; Ofloxacin; Pseudomonas Infections; Quinolones | 2006 |
European Surveillance of Antimicrobial Consumption (ESAC): outpatient quinolone use in Europe.
Topics: Anti-Bacterial Agents; Bacterial Infections; Drug Utilization; Europe; Humans; Outpatients; Quinolones | 2006 |
[Antibiotic therapy in routine medical care: progress in diagnosis of and therapy for bacterial infections (discussion)].
Topics: Anti-Bacterial Agents; Bacterial Infections; Biomarkers; C-Reactive Protein; Drug Resistance, Multiple, Bacterial; Humans; Inpatients; Methicillin Resistance; Molecular Diagnostic Techniques; Outpatients; Pneumonia, Bacterial; Practice Guidelines as Topic; Pseudomonas aeruginosa; Quinolones; Staphylococcal Infections | 2006 |
Pharmacokinetics of a single intravenous dose of marbofloxacin in adult donkeys.
Topics: Animals; Anti-Bacterial Agents; Area Under Curve; Bacterial Infections; Equidae; Female; Fluoroquinolones; Half-Life; Horse Diseases; Horses; Injections, Intravenous; Male; Metabolic Clearance Rate; Quinolones; Species Specificity; Treatment Outcome | 2007 |
Maintenance treatment with antibiotics in cystic fibrosis patients. Sense or nonsense?
Topics: Aerosols; Anti-Bacterial Agents; Bacterial Infections; Child; Child, Preschool; Cystic Fibrosis; Humans; Infant; Lung Diseases; Quinolones | 1995 |
Concentrations of OPC-17116, a new fluoroquinolone antibacterial, in serum and lung compartments.
Topics: Adult; Aged; Anti-Infective Agents; Bacterial Infections; Bronchoalveolar Lavage Fluid; Female; Fluoroquinolones; Humans; Lung; Macrophages, Alveolar; Male; Middle Aged; Mucous Membrane; Piperazines; Quinolones; Tissue Distribution | 1995 |
Evaluation of OPC-17116 against important pathogens that cause respiratory tract infections.
Topics: Animals; Anti-Infective Agents; Bacteria; Bacterial Infections; Fluoroquinolones; Male; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Piperazines; Pneumonia; Quinolones; Rats; Rats, Sprague-Dawley; Respiratory Tract Infections | 1994 |
In-vitro activity of clinafloxacin (CI-960) and PD 131628-2 against anaerobic bacteria.
Topics: Anti-Infective Agents; Bacteria, Anaerobic; Bacterial Infections; Culture Media; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Naphthyridines; Quinolones | 1994 |
Increased activity of a new chlorofluoroquinolone, BAY y 3118, compared with activities of ciprofloxacin, sparfloxacin, and other antimicrobial agents against anaerobic bacteria.
Topics: Anti-Infective Agents; Bacteria, Anaerobic; Bacterial Infections; Ciprofloxacin; Fluoroquinolones; Microbial Sensitivity Tests; Quinolones | 1994 |
European Study Group on Antibiotic Breakpoints. Breakpoint determination: sparfloxacin.
Topics: Bacterial Infections; Drug Resistance, Microbial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Quinolones | 1994 |
In vitro and in vivo evaluations of A-80556, a new fluoroquinolone.
Topics: Animals; Anti-Infective Agents; Bacteria; Bacteria, Anaerobic; Bacterial Infections; Drug Resistance, Microbial; Female; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Mice; Mice, Inbred Strains; Microbial Sensitivity Tests; Quinolones | 1994 |
In vitro antibacterial activity of AM-1155, a novel 6-fluoro-8-methoxy quinolone.
Topics: Anti-Infective Agents; Bacteria; Bacterial Infections; Drug Resistance, Microbial; Fluoroquinolones; Gatifloxacin; Humans; Japan; Microbial Sensitivity Tests; Mutation; Piperazines; Quinolones; Topoisomerase II Inhibitors | 1994 |
Mechanisms of quinolone resistance in clinical isolates: accumulation of sparfloxacin and of fluoroquinolones of various hydrophobicity, and analysis of membrane composition.
Topics: Anti-Infective Agents; Bacteria; Bacterial Infections; Bacterial Outer Membrane Proteins; Cell Membrane; Chemical Phenomena; Chemistry, Physical; DNA Topoisomerases, Type II; DNA, Bacterial; DNA, Superhelical; Drug Resistance, Microbial; Enterobacteriaceae; Escherichia coli; Fluoroquinolones; Magnesium; Pseudomonas aeruginosa; Quinolones; Staphylococcus aureus | 1993 |
Prevention of infections in the neutropenic patient.
Topics: Acute Disease; Bacterial Infections; Communicable Diseases; Humans; Infection Control; Leukemia; Neutropenia; Quinolones; Trimethoprim, Sulfamethoxazole Drug Combination | 1993 |
In vitro activity of Bay Y3118 against anaerobic bacteria.
Topics: Anti-Infective Agents; Bacteria, Anaerobic; Bacterial Infections; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Quinolones | 1993 |
In vitro activity of sparfloxacin compared with ciprofloxacin and ofloxacin against respiratory tract pathogens.
Topics: Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Ofloxacin; Quinolones; Respiratory Tract Infections | 1993 |
Temafloxacin-induced hemolytic anemia and renal failure.
Topics: Acute Kidney Injury; Anemia, Hemolytic; Anti-Infective Agents; Bacterial Infections; Erythrocytes; Female; Fluoroquinolones; Hemolysis; Humans; Immune Complex Diseases; Middle Aged; Quinolones | 1993 |
The importance of pharmacokinetics and pharmacodynamics for effective treatment of infections.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacterial Infections; Drug Administration Schedule; Half-Life; Humans; Lactams; Quinolones | 1993 |
[Rufloxacin: the first quinolone, the fruit of Italian research].
Topics: Anti-Infective Agents; Bacterial Infections; Fluoroquinolones; Humans; Quinolones; Tablets | 1993 |
Synthesis and antibacterial activity of a new series of tetracyclic pyridone carboxylic acids.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Carboxylic Acids; Escherichia coli; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Male; Mice; Molecular Structure; Piperazines; Pseudomonas aeruginosa; Pyridones; Quinolines; Quinolones; Staphylococcus aureus; Structure-Activity Relationship; Thiazoles; Topoisomerase II Inhibitors | 1993 |
Antibacterial properties of AM-1155, a new 8-methoxy quinolone.
Topics: Animals; Anti-Infective Agents; Bacteria; Bacteria, Anaerobic; Bacterial Infections; Culture Media; Fluoroquinolones; Gatifloxacin; Gram-Positive Bacteria; Hydrogen-Ion Concentration; Male; Mice; Mice, Inbred Strains; Microbial Sensitivity Tests; Piperazines; Quinolones; Time Factors | 1995 |
Pharmacokinetic study of a new quinolone, DW-116.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Dogs; Fluoroquinolones; Half-Life; Male; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley | 1995 |
In vitro antibacterial activity of DU-6859a, a new fluoroquinolone.
Topics: Anti-Infective Agents; Bacteria; Bacterial Infections; Drug Resistance, Microbial; Enzyme Inhibitors; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Mutation; Quinolones; Spiro Compounds; Topoisomerase II Inhibitors | 1995 |
In vitro and in vivo antibacterial activities of CS-940, a new 6-fluoro-8-difluoromethoxy quinolone.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Drug Evaluation, Preclinical; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Male; Mice; Naphthyridines; Piperazines; Pneumonia, Bacterial; Quinolones | 1996 |
An audit of ciprofloxacin use in severe life threatening infection at the AKUH.
Topics: Adult; Age Factors; Anti-Infective Agents; Bacterial Infections; Child; Ciprofloxacin; Humans; Infant; Infant, Newborn; Quinolones | 1996 |
Premafloxacin: a projected veterinary use fluoro-quinolone with significant activity against multi-resistant gram-positive human pathogens.
Topics: Anti-Infective Agents; Bacterial Infections; Drug Resistance, Multiple; Fluoroquinolones; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Pyrroles; Quinolones | 1996 |
In vitro activity of quinolones and other antimicrobial agents against anaerobic bacteria.
Topics: Anti-Infective Agents; Bacteria, Anaerobic; Bacterial Infections; Drug Resistance, Microbial; Fluoroquinolones; Humans; Imipenem; In Vitro Techniques; Metronidazole; Microbial Sensitivity Tests; Quinolones | 1996 |
Comparison of in vitro activities of DU-6859a and other fluoroquinolones against Japanese isolates of anaerobic bacteria.
Topics: Administration, Oral; Anti-Infective Agents; Bacteria, Anaerobic; Bacterial Infections; Bacteroides fragilis; Bacteroides Infections; Female; Fluoroquinolones; Gardnerella vaginalis; Humans; In Vitro Techniques; Japan; Microbial Sensitivity Tests; Quinolones; Vaginosis, Bacterial | 1996 |
Comparison of the in vitro activities of Bay 12-8039, a new quinolone, and other antimicrobials against clinically important anaerobes.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria, Anaerobic; Bacterial Infections; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Quinolones | 1997 |
In-vitro and in-vivo activities of DW-116, a new fluoroquinolone.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Dose-Response Relationship, Drug; Enterococcus faecalis; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Male; Methicillin Resistance; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Ofloxacin; Piperazines; Pseudomonas aeruginosa; Quinolones; Staphylococcus aureus | 1997 |
In vitro activity of premafloxacin, a new extended-spectrum fluoroquinolone, against pathogens of veterinary importance.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Microbial Sensitivity Tests; Pyrroles; Quinolones | 1997 |
In vitro and in vivo antibacterial efficacies of CFC-222, a new fluoroquinolone.
Topics: Animals; Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Culture Media; Fluoroquinolones; Mice; Microbial Sensitivity Tests; Ofloxacin; Quinolones | 1997 |
[Clinical and microbiological investigations of atrophic rhinitis of Upper Austrian swine herds].
Topics: Agricultural Workers' Diseases; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Austria; Bacteria; Bacterial Infections; Enrofloxacin; Fluoroquinolones; Lincomycin; Microbial Sensitivity Tests; Nasal Mucosa; Penicillins; Quinolones; Rhinitis, Atrophic; Spectinomycin; Swine | 1997 |
Comparative in-vitro and in-vivo activity of AM-1155 against anaerobic bacteria.
Topics: Animals; Anti-Infective Agents; Bacteria, Anaerobic; Bacterial Infections; Cecum; Fluoroquinolones; Gatifloxacin; Granuloma; Mice; Mice, Inbred Strains; Microbial Sensitivity Tests; Piperazines; Quinolones; Rats | 1997 |
The activity of grepafloxacin against respiratory pathogens in the UK.
Topics: Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Drug Resistance, Microbial; England; Fluoroquinolones; Haemophilus influenzae; Humans; Microbial Sensitivity Tests; Moraxella catarrhalis; Penicillin Resistance; Penicillins; Piperazines; Quinolones; Respiratory Tract Infections; Retrospective Studies; Streptococcus pneumoniae | 1997 |
In-vitro and in-vivo antibacterial activity of CFC-222, a new fluoroquinolone.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Fluoroquinolones; Male; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Ofloxacin; Quinolones | 1998 |
Bacterial eradication by clinafloxacin, CI-990, and ciprofloxacin employing MBC test, in-vitro time-kill and in-vivo time-kill studies.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Mice; Microbial Sensitivity Tests; Naphthyridines; Quinolones | 1998 |
Pharmacokinetics of enrofloxacin after intravenous, intramuscular and oral administration in houbara bustard (Chlamydotis undulata macqueenii).
Topics: Administration, Oral; Animals; Anti-Infective Agents; Area Under Curve; Bacterial Infections; Bird Diseases; Birds; Enrofloxacin; Fluoroquinolones; Injections, Intramuscular; Injections, Intravenous; Microbial Sensitivity Tests; Pilot Projects; Quinolones | 1998 |
The acute phase response in the Sudan plated lizard, Gerrhosaurus major.
Topics: Acute-Phase Reaction; Aeromonas; Animals; Anti-Infective Agents; Bacterial Infections; Body Temperature Regulation; Enrofloxacin; Fluoroquinolones; Iron; Lizards; Quinolones; Zinc | 1998 |
Safety profile of sparfloxacin, a new fluoroquinolone antibiotic.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Bacterial Infections; Bronchitis; Clinical Trials, Phase III as Topic; Community-Acquired Infections; Data Interpretation, Statistical; Female; Fluoroquinolones; Heart Rate; Humans; Male; Middle Aged; Photosensitivity Disorders; Pneumonia, Bacterial; Quinolones; Sinusitis; Skin Diseases, Bacterial | 1999 |
In vitro and in vivo antimicrobial activities of T-3811ME, a novel des-F(6)-quinolone.
Topics: Administration, Oral; Animals; Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Fluoroquinolones; Indoles; Injections, Subcutaneous; Isoindoles; Male; Mice; Naphthyridines; Ofloxacin; Quinolones | 1999 |
Pre-existing bacterial infections, not stress fever, influenced previous studies which labeled Gerrhosaurus major an afebrile lizard species.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Body Temperature Regulation; Enrofloxacin; Fever; Fluoroquinolones; Lizards; Quinolones; Stress, Physiological | 1999 |
Emergence of resistance to fluoroquinolones among bacteria causing infections in food animals in Denmark.
Topics: Animals; Anti-Infective Agents; Bacteria; Bacterial Infections; Cattle; Cattle Diseases; Drug Resistance, Microbial; Enrofloxacin; Fluoroquinolones; Food Microbiology; Microbial Sensitivity Tests; Quinolones; Swine; Swine Diseases | 2000 |
Serum concentrations and pharmacokinetics of enrofloxacin after intravenous and intragastric administration to mares.
Topics: Absorption; Animals; Anti-Infective Agents; Antineoplastic Agents; Bacterial Infections; Biological Availability; Chemistry, Pharmaceutical; Enrofloxacin; Female; Fluoroquinolones; Horses; Infusions, Intravenous; Infusions, Parenteral; Quinolones | 2000 |
Effect of enrofloxacin-Na against pathogens related to the respiratory and alimentary diseases in suckling and weanling piglets.
Topics: Animals; Animals, Suckling; Anti-Infective Agents; Antibiotic Prophylaxis; Bacteria; Bacterial Infections; Digestive System Diseases; Enrofloxacin; Fluoroquinolones; Microbial Sensitivity Tests; Quinolones; Respiratory Tract Infections; Swine; Swine Diseases; Weaning | 2001 |
The in vivo activity of olamufloxacin (HSR-903) in systemic and urinary tract infections in mice.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Fluoroquinolones; Male; Mice; Mice, Inbred ICR; Quinolones; Urinary Tract Infections | 2001 |
[How can we protect against broad-band pathogens? The situation with quinolone resistance].
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Drug Resistance, Microbial; Germany; Humans; Quinolones; Time Factors | 2001 |
Antibacterial activities and pharmacokinetics of E-4767 and E-5065, two new 8-chlorofluoroquinolones with a 7-azetidin ring substituent.
Topics: Animals; Anti-Infective Agents; Azetidines; Bacteria; Bacterial Infections; Culture Media; Culture Media, Serum-Free; Fluoroquinolones; Hydrogen-Ion Concentration; Magnesium; Male; Mice; Microbial Sensitivity Tests; Quinolones | 2001 |
In vitro antibacterial activities of DQ-113, a potent quinolone, against clinical isolates.
Topics: Anti-Infective Agents; Bacteria; Bacterial Infections; Drug Resistance, Microbial; Drug Resistance, Multiple; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Microbial Sensitivity Tests; Quinolones | 2002 |
BMS284756 (formerly T-3811, a des-fluoroquinolone) potency and spectrum tested against over 10,000 bacterial bloodstream infection isolates from the SENTRY antimicrobial surveillance programme (2000).
Topics: Anti-Infective Agents; Bacteria; Bacterial Infections; Drug Resistance, Microbial; Fluoroquinolones; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Indoles; Microbial Sensitivity Tests; Population Surveillance; Quinolones | 2002 |
The use of liposomal enrofloxacin for intracellular infections in Kangal dogs and visualization of phagocytosis of liposomes.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Dog Diseases; Dogs; Drug Carriers; Enrofloxacin; Fluoroquinolones; Liposomes; Macrophages; Monocytes; Neutrophils; Phagocytosis; Quinolones; Staphylococcal Infections; Staphylococcus aureus | 2002 |
Studies show new macrolide antibiotics to be superior to some older agents.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Clarithromycin; Drug Administration Schedule; Erythromycin; Fluoroquinolones; Humans; Quinolones | 1992 |
Synthesis and structure-activity relationships of 7-diazabicycloalkylquinolones, including danofloxacin, a new quinolone antibacterial agent for veterinary medicine.
Topics: Actinobacillus Infections; Actinobacillus pleuropneumoniae; Aerobiosis; Anaerobiosis; Animals; Anti-Infective Agents; Bacterial Infections; Cattle; Cattle Diseases; Female; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Mice; Molecular Structure; Pasteurella Infections; Quinolones; Structure-Activity Relationship; Swine; Swine Diseases | 1992 |
[Clinical and bacteriological study of sparfloxacin on bacterial prostatitis].
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Bacteria; Bacterial Infections; Drug Evaluation; Fluoroquinolones; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Prostatitis; Quinolones | 1992 |
Oral temafloxacin approved for U.S. market.
Topics: Administration, Oral; Anti-Infective Agents; Bacterial Infections; Fluoroquinolones; Humans; Quinolones; United States; United States Food and Drug Administration | 1992 |
Lomefloxacin reaches U.S. market.
Topics: Anti-Infective Agents; Bacterial Infections; Fluoroquinolones; Humans; Quinolones; United States; United States Food and Drug Administration | 1992 |
In vitro activity of sparfloxacin (AT-4140), a new quinolone agent, against invasive isolates from pediatric patients.
Topics: Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Humans; Infant; Infant, Newborn; Microbial Sensitivity Tests; Mutation; Quinolones | 1992 |
In vitro and in vivo antibacterial activities of a new quinolone, OPC-17116.
Topics: Administration, Oral; Animals; Anti-Infective Agents; Bacterial Infections; Female; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Piperazines; Quinolones; Tissue Distribution | 1992 |
In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; DNA Topoisomerases, Type II; Drug Evaluation, Preclinical; Fluoroquinolones; Gatifloxacin; Male; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Norfloxacin; Ofloxacin; Piperazines; Quinolones; Tissue Distribution | 1992 |
Susceptibility of recent clinical isolates to temafloxacin (A-63004) and other antimicrobial agents.
Topics: Anti-Infective Agents; Bacteria; Bacterial Infections; Drug Resistance, Microbial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Quinolones | 1992 |
In vitro and in vivo evaluation of BMY 45243, a new 5-amino-naphthyridone derivative.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Female; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Mice; Microbial Sensitivity Tests; Naphthyridines; Quinolones; Solubility | 1992 |
[Theoretical research for therapy of infection].
Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; Humans; Lactams; Quinolones; Time Factors | 1991 |
[Continuous treatment after parenteral cephalosporins. Peroral treatment is not available but temporary alternatives exist].
Topics: Administration, Oral; Anti-Bacterial Agents; Bacterial Infections; Cephalosporins; Humans; Injections, Intravenous; Quinolones | 1991 |
Fluoroquinolones in the treatment of human infection: the role of temafloxacin.
Topics: Anti-Infective Agents; Bacteria; Bacterial Infections; Fluoroquinolones; Humans; Quinolones | 1991 |
Temafloxacin: a safe antibiotic for the elderly, patients with comorbidities, and other special populations.
Topics: Age Factors; Aged; Anti-Infective Agents; Bacterial Infections; Drug Interactions; Female; Fluoroquinolones; Humans; Kidney Diseases; Male; Quinolones; Risk Factors; Sex Factors | 1991 |
Clinical results using two new antibiotics--clarithromycin and temafloxacin.
Topics: Acquired Immunodeficiency Syndrome; Anti-Infective Agents; Bacterial Infections; Clarithromycin; Erythromycin; Fluoroquinolones; Humans; Opportunistic Infections; Quinolones | 1991 |
ESGAB breakpoint determination: temafloxacin.
Topics: Anti-Infective Agents; Bacteria; Bacterial Infections; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Quinolones | 1991 |
Dual-action cephalosporins: cephalosporin 3'-quaternary ammonium quinolones.
Topics: Animals; Bacterial Infections; Cephalosporins; Chemical Phenomena; Chemistry; Mice; Microbial Sensitivity Tests; Quinolones; Structure-Activity Relationship | 1991 |
Enrofloxacin in salmonids.
Topics: 4-Quinolones; Administration, Oral; Aeromonas; Animals; Anti-Infective Agents; Bacterial Infections; Enrofloxacin; Fish Diseases; Fluoroquinolones; Quinolones; Trout | 1991 |
[Usage of antibiotics in routine clinical therapy].
Topics: Anti-Bacterial Agents; Bacterial Infections; Bronchiolitis; Drug Therapy, Combination; Erythromycin; Humans; Lactams; Methicillin Resistance; Quinolones; Staphylococcal Infections | 1990 |
Activity of temafloxacin against respiratory pathogens.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Cells, Cultured; Ciprofloxacin; Dose-Response Relationship, Drug; Female; Fluoroquinolones; Gerbillinae; Gram-Positive Bacteria; Guinea Pigs; Male; Mice; Microbial Sensitivity Tests; Ofloxacin; Quinolones; Respiratory Tract Infections | 1991 |
In vitro and in vivo antibacterial activities of E-4497, a new 3-amine-3-methyl-azetidinyl tricyclic fluoroquinolone.
Topics: Animals; Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Drug Evaluation, Preclinical; Drug Interactions; Fluoroquinolones; Magnesium; Male; Mice; Microbial Sensitivity Tests; Norfloxacin; Ofloxacin; Quinolones | 1991 |
[Enrofloxacin, a new drug for ornamental fish].
Topics: 4-Quinolones; Animals; Anti-Infective Agents; Bacterial Infections; Enrofloxacin; Fish Diseases; Fishes; Fluoroquinolones; Quinolones | 1990 |
New quinolone antibacterial agents. Synthesis and biological activity of 7-(3,3- or 3,4-disubstituted-1-pyrrolidinyl)quinoline-3-carboxylic acids.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Chemical Phenomena; Chemistry, Physical; Magnetic Resonance Spectroscopy; Mice; Microbial Sensitivity Tests; Quinolones; Structure-Activity Relationship | 1990 |
In-vitro activity of PD 117 596, a new quinolone, against bacterial isolates from cancer patients.
Topics: Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Neoplasms; Quinolones | 1990 |
In vitro and in vivo activities of a new quinolone, WIN 57273, possessing potent activity against gram-positive bacteria.
Topics: 4-Quinolones; Animals; Anti-Infective Agents; Bacterial Infections; Female; Fluoroquinolones; Gram-Positive Bacteria; Listeriosis; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Quinolones; Staphylococcal Infections; Streptococcal Infections | 1990 |
[The new quinolones].
Topics: Anti-Bacterial Agents; Bacterial Infections; Bone Diseases; Digestive System Diseases; Drug Therapy, Combination; Humans; Quinolones; Respiratory Tract Infections; Urinary Tract Infections | 1989 |
[On the contribution by F. Daschner and I. Kappstein: "Quinolones: significance and problems in clinical practice" in Internist, Volume 29, issue 3, March 1988, p. 206-212].
Topics: Bacteria; Bacterial Infections; Drug Resistance, Microbial; Humans; Quinolones | 1989 |
[Antimicrobial chemotherapy--its clinico-pharmacologic significance].
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacterial Infections; Cephalosporins; Humans; Quinolones | 1989 |
In vitro and in vivo antibacterial activities of KB-5246, a new tetracyclic quinolone.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Fluoroquinolones; Male; Mice; Microbial Sensitivity Tests; Norfloxacin; Ofloxacin; Phenalenes; Quinolones | 1989 |
In-vitro activity of PD 117558, a new quinolone against bacterial isolates from cancer patients.
Topics: 4-Quinolones; Anti-Infective Agents; Bacteria; Bacterial Infections; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Neoplasms; Quinolones | 1989 |
Rufloxacin (MF-934): in vitro and in vivo antibacterial activity.
Topics: 4-Quinolones; Animals; Anti-Infective Agents; Bacteria; Bacterial Infections; Female; Fluoroquinolones; Male; Mice; Microbial Sensitivity Tests; Quinolones; Respiratory Tract Infections; Skin Diseases, Infectious | 1989 |
[Studies of lomefloxacin in biliary tract infections].
Topics: 4-Quinolones; Adult; Aged; Anti-Infective Agents; Bacteria; Bacterial Infections; Biliary Tract Diseases; Drug Evaluation; Drug Resistance, Microbial; Female; Fluoroquinolones; Humans; Male; Middle Aged; Quinolones | 1989 |
[Recent progress in antimicrobial agents].
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Drug Resistance, Microbial; Humans; Imipenem; Quinolones | 1988 |
Laboratory assessment of lomefloxacin (SC-47111) in comparison with norfloxacin.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Norfloxacin; Quinolones; Staphylococcus | 1988 |
[Chemotherapy for biliary tract infection (XXXIII). Tissue concentration of NY-198 in gallbladder, biliary excretion and clinical effects].
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bacterial Infections; Bile; Cholangitis; Cholecystitis; Drug Evaluation; Enoxacin; Female; Fluoroquinolones; Gallbladder; Humans; Male; Middle Aged; Quinolones; Tissue Distribution | 1988 |
In vitro and in vivo activity of NY-198, a new difluorinated quinolone.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Fluoroquinolones; Male; Mice; Microbial Sensitivity Tests; Norfloxacin; Ofloxacin; Oxazines; Pipemidic Acid; Quinolines; Quinolones | 1987 |
In vitro antibacterial activity of E-3604, a new 6-fluoroquinolone, on clinical isolates.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Fluoroquinolones; Humans; Hydrogen-Ion Concentration; Microbial Sensitivity Tests; Norfloxacin; Quinolines; Quinolones | 1987 |